Centro de marca | Envases farmacéuticos de LINUO
December 31, 2025 17:01
New Year Message from Song Lai, Chairman of Linuo Pharmaceutical Packaging
Dear investors, partners, and all colleagues,
Con motivo de despedir el año viejo y dar la bienvenida al nuevo, quisiera expresar, en nombre del Consejo de Administración de Linuo Pharmaceutical Packaging, nuestro más sincero agradecimiento y nuestros mejores deseos de Año Nuevo a todos los inversores, accionistas, socios y amigos de todos los sectores que han confiado durante tanto tiempo en el desarrollo de nuestra empresa, lo han apoyado y se han preocupado por él.
2025 marks the final year of China’s 14th Five-Year Plan, as well as the year of strategic planning for the 15th Five-Year Plan. It is also a milestone year for Linuo Pharmaceutical Packaging as we celebrate “Thirty Years of Strength, Embarking on a New Journey.” Over the past year, Linuo Pharmaceutical Packaging has achieved systematic breakthroughs in globalization, industrial integration, and organic growth.
We not only established strategic cooperation with Brazil’s SANTISA and Xseer in the United States, acquired equity in Chuangyang New Materials, and rapidly expanded into high-growth markets such as South America and the Middle East; we also strengthened supply chain independence and accelerated our strategic advancement toward high-end manufacturing. Capital investment has been focused on premium products such as Ready-to-Use (RTU) packaging and Prefilled Syringes (PFS). The commissioning of our second Type I borosilicate molded glass production furnace marks the official release of additional core production capacity.
Linuo Pharmaceutical Packaging established its wholly owned subsidiary, Shandong Linuo Intelligent Robot Co., Ltd., entering the intelligent robotics sector and achieving strategic expansion beyond its core business. Meanwhile, Linuo Special Glass (LINUO TGB) has expanded internationally under its independent global brand Borohouse, achieving a comprehensive upgrade from traditional manufacturing output to an integrated operation model combining brand, technology, channels, and e-commerce. This transformation has created a more certain and sustainable growth pathway for the company’s future global performance.
At the same time, we continue to transform these strategic achievements into sustainable growth momentum and long-term shareholder value returns. Through steady performance and a clear strategic roadmap, we strive to reward every share of trust and expectation placed in us.
The current capital market is undergoing profound structural transformation. Facing the shift in evaluation standards from “scale and speed” toward “quality and efficiency,” Linuo Pharmaceutical Packaging has proactively embraced change and positioned its strategic focus around a new development philosophy of “high quality, high efficiency, and high value.”
The year 2026 will be a highly challenging year, but also one filled with opportunities. Linuo Pharmaceutical Packaging will continue strengthening its industrial foundation, enhancing brand influence, and maximizing value creation for investors and shareholders.
In 2026, we will transform policy opportunities into growth momentum, continuously optimize corporate governance, and officially launch the “Five New Eras” of development:
investment and financing, technological innovation, data management, AI full-scenario applications, and internet-driven thinking.
Through integrated approaches including cultural marketing, digital marketing, and innovative marketing, we will accelerate market activation. We will continue to make technological innovation, brand enhancement, intelligent digital transformation, and global expansion the strategic pillars of our development, while optimizing and strengthening our core business lines, focusing on key businesses, and simplifying organizational structures.
We will truly practice our core values of “Product Excellence, Long-Term Commitment, and Creating Value for Others.”
As a new year begins, our original aspiration remains unwavering. We firmly believe that only companies that continuously create real value can overcome cycles and win the future.
The management team and all employees of Linuo Pharmaceutical Packaging are ready to move forward with determination and action, working hand in hand with our investors to embrace a more fruitful and successful 2026, and to share the long-term returns brought by the company’s high-quality development.
Once again, we sincerely wish everyone a Happy New Year, good health and happiness for your families, and continued success in your investments!
Produced by | Brand Center
Written & Designed by | Qi Jinlong
Fuente de la imagen | Li Jiakai
Responsible Editor | Mei Jinjiao
Preguntas frecuentes
What were LINUO Pharmaceutical Packaging’s key achievements in 2025?
In 2025, LINUO Pharmaceutical Packaging made progress in globalization, industrial integration, and organic growth. The company established strategic cooperation with SANTISA in Brazil and Xseer in the United States, acquired equity in Chuangyang New Materials, expanded into markets including South America and the Middle East, and increased investment in high-value pharmaceutical packaging products such as RTU packaging and Prefilled Syringes (PFS).
How is LINUO Pharmaceutical Packaging expanding its global presence?
LINUO Pharmaceutical Packaging is strengthening its international presence through strategic cooperation, overseas market development, brand building, and channel expansion. In 2025, the company highlighted cooperation with partners in Brazil and the United States and continued expanding in markets such as South America and the Middle East.
Which pharmaceutical packaging businesses is LINUO focusing on for future growth?
LINUO Pharmaceutical Packaging is directing investment toward higher-value pharmaceutical packaging businesses, including Ready-to-Use (RTU) packaging and Prefilled Syringes (PFS). These areas are part of the company’s broader strategy to strengthen high-end manufacturing and improve long-term growth potential.
How did LINUO expand its Type I borosilicate molded glass production capacity?
LINUO Pharmaceutical Packaging commissioned its second Type I borosilicate molded glass production furnace in 2025. According to the company, this milestone released additional core production capacity and strengthened its manufacturing foundation for pharmaceutical glass packaging.
What are LINUO Pharmaceutical Packaging’s “Five New Eras” for 2026?
LINUO Pharmaceutical Packaging plans to focus on five major development areas in 2026: investment and financing, technological innovation, data management, AI full-scenario applications, and internet-driven thinking. These areas are intended to support higher-quality, higher-efficiency, and higher-value growth.
What are LINUO Pharmaceutical Packaging’s main strategic priorities for 2026?
In 2026, LINUO Pharmaceutical Packaging plans to continue strengthening technological innovation, brand development, intelligent digital transformation, and global expansion. The company also aims to optimize its core businesses, simplify organizational structures, improve corporate governance, and create greater long-term value for investors, customers, and partners.
31 de diciembre de 2025 
